CDA | Evidence Driven
CDA | Evidence Driven

Alecensaro for Non-Small Cell Lung Cancer (first line) – Details

Details

Files
Generic Name:
Alectinib
Project Status:
Complete
Therapeutic Area:
Locally advanced or metastatic ALK+ NSCLC (first line)
Manufacturer:
Hoffmann-La Roche Limited
Brand Name:
Alecensaro
Project Line:
Reimbursement Review
Project Number:
PC0125-000
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Strength:
150 mg
Tumour Type:
Lung
Indications:
Non-Small Cell Lung Cancer (first line)
Funding Request:
For the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced or metastatic non-small cell lung cancer
Pre Noc Submission:
Yes
Sponsor:
Hoffmann-La Roche Limited
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Alectinib (Alecensaro) NSCLC (first line) - pERC Final Recommendation Final Recommendation July 25, 2018 View PDF
Alectinib (Alecensaro) NSCLC (first line) - Final Clinical Guidance Report Guidance Reports July 25, 2018 View PDF
Alectinib (Alecensaro) NSCLC (first line) - Final Economic Guidance Report Guidance Reports July 25, 2018 View PDF
Alectinib (Alecensaro) NSCLC (first line) - pERC Initial Recommendation Initial Recommendation July 6, 2018 View PDF
Alectinib (Alecensaro) NSCLC (first line) - PAG Feedback on pERC Initial Recommendation Feedback July 25, 2018 View PDF
Alectinib (Alecensaro) NSCLC (first line) - Manufacturer Feedback on pERC Initial Recommendation Feedback July 25, 2018 View PDF
Alectinib (Alecensaro) NSCLC (first line) - Clinician Feedback on Initial Recommendation Feedback July 25, 2018 View PDF
Alectinib (Alecensaro) NSCLC (first line) - Patient Group COI Declarations COI Declarations July 25, 2018 View PDF
Alectinib (Alecensaro) NSCLC (first line) - Clinician COI Declarations COI Declarations July 25, 2018 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : August 13, 2018